74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
74%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
74%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Fate Therapeutics Inc
Closed
SectorHealthcare
0.75 8.7
Overview
Share price change
24h
Min
0.69
Max
0.75
Income | -4.5M -52M |
|---|---|
Sales | -1.2M 1.9M |
EPS | -0.44 |
Profit margin | -2,803.925 |
Employees | 181 |
EBITDA | 10M -42M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +722.67% upside |
Next Earnings | 8 May 2025 |
|---|
Market Cap | -20M 97M |
|---|---|
Previous open | -7.95 |
Previous close | 0.75 |
News Sentiment
By Acuity
11%
89%
12 / 386 Healthcare
Technical Score
By Trading Central
Confidence
Weak Bearish Evidence
Fate Therapeutics Inc Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Fate Therapeutics Inc Forecast
Price Target
By TipRanks
722.67% upside
12 Months Forecast
Average 6.17 USD 722.67%
High 12 USD
Low 2.5 USD
Based on 12 Wall Street analysts offering 12 month price targets forFate Therapeutics Inc - Dist in the last 3 months.
Sentiment
By Acuity
12 / 386 Healthcare
News Sentiment
Very Strong Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Fate Therapeutics Inc
Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.
